TD Cowen on Rapport Therapeutics (RAPP): 'Meaningful upside remains'

October 20, 2026 9:55 AM EDT Send to a Friend
TD Cowen analyst Joseph Thome reiterated a Buy rating on Rapport Therapeutics (NASDAQ: RAPP).The analyst comments "RAPP announced that the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login